- Home
- STRO vs RCKT Comparison
STRO vs RCKT Comparison
Compare STRO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRO | RCKT |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.8M | 394.2M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | STRO | RCKT |
|---|---|---|
| Price | $16.91 | $3.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $31.33 | $29.73 |
| AVG Volume (30 Days) | 207.3K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $38,419,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | ★ N/A | $5.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $2.53 |
| 52 Week High | $43.85 | $5.45 |
Technical Indicators
Market Signals| Indicator | STRO | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 41.37 |
| Support Level | $10.34 | $3.03 |
| Resistance Level | $17.33 | $3.65 |
| Average True Range (ATR) | 0.99 | 0.20 |
| MACD | -0.24 | -0.05 |
| Stochastic Oscillator | 9.16 | 8.11 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.